AveX­is shares spike on more pos­i­tive da­ta for SMA gene ther­a­py; Bio­gen stock tanks on fresh skep­ti­cism

→ AveX­is $AVXS says that 12 of the 12 in­fants suf­fer­ing from spinal mus­cu­lar at­ro­phy (SMA) who were treat­ed with AVXS-101 reached 13.6 months …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.